Akebia begins dosing patients in Phase 1 trial of AKB-9090

April 13, 2026 8:03 AM

Akebia Therapeutics Inc. (NASDAQ: AKBA) announced that it has begun dosing participants in a Phase 1 clinical trial of AKB-9090 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found